{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T07:03:41Z","timestamp":1790233421934,"version":"4.1.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Prednisone 5 mg\/day suppresses multiple indices of bone formation in a randomized placebo-controlled trial in healthy postmenopausal females. This suggests that even low doses of prednisone may reduce bone repair or renewal and may have adverse effects on bone mass and\/or bone strength.<\/jats:p>\n               <jats:p>Introduction: High doses of chronic glucocorticoids are known to have adverse effects on bone, and measures to prevent bone loss are well established for doses &amp;gt;7.5 mg daily, because these doses can cause premature or exaggerated osteoporosis. However, it is unclear if chronic prednisone doses of 5 mg daily have the same effects on bone. There are no established recommendations for preventing glucocorticoid-induced osteoporosis in people taking prednisone 5 mg daily, a dose used frequently in medical practice to treat diseases of the lungs, joints, skin, muscles, eyes, nerves, etc. Our primary objective was to test whether prednisone 5 mg daily affects serum and urine indices of bone metabolism in healthy postmenopausal women. Our secondary objectives were to determine if prednisone 5 mg affected systolic or diastolic blood pressure or causes side effects.<\/jats:p>\n               <jats:p>Materials and Methods: A double-blinded randomized placebo-controlled 8-week trial in 50 healthy postmenopausal women was conducted at the Massachusetts General Hospital Outpatient General Clinical Research Center. Patients were randomly assigned to prednisone 5 mg daily or matching placebo for 6 weeks, followed by a 2-week recovery phase. Markers of bone formation and resorption were determined at weeks 0, 2, 4, 6, and 8. Indices of osteoblast activity included serum propeptide of type I N-terminal procollagen (PINP), propeptide of type I C-terminal procollagen (PICP), osteocalcin, and bone-specific alkaline phosphatase (BSALP). Indices of osteoclast activity included urine and serum type I collagen N-telopeptide (NTX) and free urinary deoxypyridinoline (DPD).<\/jats:p>\n               <jats:p>Results and Conclusions: Prednisone rapidly and significantly decreased serum PINP (p &amp;lt; 0.01), PICP (p &amp;lt; 0.01), and osteocalcin (p &amp;lt; 0.01) and free urinary deoxypyridinoline (p = 0.017). These changes were largely reversed during the recovery period. Side effects were indistinguishable in the two groups. Neither systolic nor diastolic blood pressure changed significantly throughout the study between the two groups. In conclusion, low-dose prednisone significantly decreases indices of bone formation and may decrease indices of bone resorption in postmenopausal women. Further studies are needed to assess the effects of low-dose prednisone on BMD and fracture risk.<\/jats:p>","DOI":"10.1359\/jbmr.041125","type":"journal-article","created":{"date-parts":[[2006,4,27]],"date-time":"2006-04-27T08:26:11Z","timestamp":1146126371000},"page":"464-470","source":"Crossref","is-referenced-by-count":181,"title":["Effects of Low-Dose Prednisone on Bone Metabolism"],"prefix":"10.1093","volume":"20","author":[{"given":"Francine N","family":"Ton","sequence":"first","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Rheumatology, Allergy, and Immunology Unit, Massachusetts General Hospital, Boston, Massachusetts, USA"},{"name":"Endocrinology Unit, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha C","family":"Gunawardene","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Lee","sequence":"additional","affiliation":[{"name":"Biostatistics Center, Massachusetts General Hospital, Boston, Massachusetts, USA"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M","family":"Neer","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Endocrinology Unit, Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,12,4]]},"reference":[{"key":"2024013019225829300_bib1","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/BF02405356","article-title":"Bone loss after glucocorticoid therapy","volume":"36","author":"Lo Cascio","year":"1984","journal-title":"Calcif Tissue Int"},{"key":"2024013019225829300_bib2","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1210\/jcem-62-5-1056","article-title":"Serum osteocalcin is increased in patients with hyperthyroidism and decreased in patients receiving glucocorticoids","volume":"62","author":"Lukert","year":"1986","journal-title":"J Clin Endocrinol Metab"},{"key":"2024013019225829300_bib3","first-page":"506","volume-title":"Fourth International Symposium on Osteoporosis","author":"Raisz","year":"1993"},{"key":"2024013019225829300_bib4","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0889-857X(21)00353-7","article-title":"Glucocorticoid-induced osteoporosis","volume":"20","author":"Lukert","year":"1994","journal-title":"Rheum Dis Clin North Am"},{"key":"2024013019225829300_bib5","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0022-4731(81)90270-3","article-title":"Pathophysiology of the adverse effects of glucoactive corticosteroids on calcium metabolism on man","volume":"15","author":"Canniggia","year":"1981","journal-title":"J Steroid Biochem"},{"key":"2024013019225829300_bib6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/rheumatology\/37.1.27","article-title":"Effect of low-dose prednisone (with calcium and calcitriol supplementation) on calcium and bone metabolism in healthy volunteers","volume":"37","author":"Lems","year":"1998","journal-title":"Br J Rheumatol"},{"key":"2024013019225829300_bib7","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s002239900482","article-title":"Age-dependent effect of oral glucocorticoids on markers of bone resorption in patients with acute asthma","volume":"63","author":"Bornefalk","year":"1998","journal-title":"Calcif Tissue Int"},{"key":"2024013019225829300_bib8","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/rheumatology\/39.5.523","article-title":"Acute effects of etidronate on glucocorticoid-induced bone degradation","volume":"39","author":"Struijs","year":"2000","journal-title":"Rheumatology (Oxford)"},{"key":"2024013019225829300_bib9","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1210\/jcem-72-2-382","article-title":"The course of biochemical parameters of bone turnover during treatment with corticosteroids","volume":"72","author":"Prummel","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"2024013019225829300_bib10","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1001\/archinte.1990.00390230093012","article-title":"Determinants of vertebral mineral density in patients receiving long- term glucocorticoid therapy","volume":"150","author":"Reid","year":"1990","journal-title":"Arch Intern Med"},{"key":"2024013019225829300_bib11","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0002-9343(94)90131-7","article-title":"Low dose long-term corticosteroid therapy in rheumatoid arthritis: An analysis of serious adverse events","volume":"96","author":"Saag","year":"1994","journal-title":"Am J Med"},{"key":"2024013019225829300_bib12","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0950-3579(05)80080-9","article-title":"Corticosteroid osteoporosis","volume":"7","author":"Reid","year":"1993","journal-title":"Baillieres Clin Rheumatol"},{"key":"2024013019225829300_bib13","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1136\/ard.54.1.49","article-title":"Rheumatoid arthritis, corticosteroid therapy and hip fracture","volume":"54","author":"Cooper","year":"1995","journal-title":"Ann Rheum Dis"},{"key":"2024013019225829300_bib14","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0889-857X(05)70196-4","article-title":"An update on glucocorticoid-induced osteoporosis","volume":"27","author":"Lane","year":"2001","journal-title":"Rheum Dis Clin North Am"},{"key":"2024013019225829300_bib15","volume-title":"Rheumatology","author":"Klippel","year":"1998"},{"key":"2024013019225829300_bib16","volume-title":"Kelley's Textbook of Rheumatology","author":"Ruddy","year":"2001"},{"key":"2024013019225829300_bib17","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1359\/jbmr.2000.15.6.993","article-title":"Use of oral corticosteroids and risk of fractures","volume":"15","author":"Van Staa","year":"2000","journal-title":"J Bone Miner Res"},{"issue":"Suppl 1","key":"2024013019225829300_bib18","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s003930070039","article-title":"Corticosteroid osteoporosis","volume":"59","author":"Sambrook","year":"2000","journal-title":"Z Rheumatol"},{"key":"2024013019225829300_bib19","first-page":"2582","article-title":"A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid Arthritis","volume":"27","author":"Sinigaglia","year":"2000","journal-title":"J Rheumatol"},{"key":"2024013019225829300_bib20","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s001980200108","article-title":"The epidemiology of corticosteroid-induced osteoporosis: A meta-analysis","volume":"13","author":"van Staa","year":"2002","journal-title":"Osteoporos Int"},{"key":"2024013019225829300_bib21","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/jnci\/87.17.1297","article-title":"Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women","volume":"87","author":"Hankinson","year":"1995","journal-title":"J Natl Cancer Inst"},{"key":"2024013019225829300_bib22","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/clinchem\/20.3.365","article-title":"Single-antibody technique for radioimmunoassay of cortisol in unextracted serum or plasma","volume":"20","author":"Foster","year":"1974","journal-title":"Clin Chem"},{"key":"2024013019225829300_bib23","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1359\/jbmr.1998.13.7.1124","article-title":"Response of biochemical markers of bone turnover to hormone replacement therapy: Impact of biological variability","volume":"13","author":"Hannon","year":"1998","journal-title":"J Bone Miner Res"},{"key":"2024013019225829300_bib24","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1080\/00365519950185229","article-title":"Current databases on biological variation: Pros, cons and progress","volume":"59","author":"Ricos","year":"1999","journal-title":"Scand J Clin Lab Invest"},{"key":"2024013019225829300_bib25","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1093\/rheumatology\/39.12.1383","article-title":"Oral corticosteroids and fracture risk: Relationship to daily and cumulative doses","volume":"39","author":"van Staa","year":"2000","journal-title":"Rheumatol"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1359%2FJBMR.041125","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/20\/3\/464\/56476079\/5650200311.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/20\/3\/464\/56476079\/5650200311.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T15:07:54Z","timestamp":1710342474000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/20\/3\/464-470\/7592938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3,1]]},"references-count":25,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2009,12,4]]},"published-print":{"date-parts":[[2005,3,1]]}},"URL":"https:\/\/doi.org\/10.1359\/jbmr.041125","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2005,3,1]]},"published":{"date-parts":[[2005,3,1]]}}}